EU Experts Recommend Approval of Gilead's COVID-19 Drug
After Gilead Sciences (NASDAQ: GILD) reported encouraging phase 3 clinical trial data in COVID-19 patients earlier this month, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval, clearing the way for remdesivir to become the first drug specifically OK'd to treat COVID-19 in the European Union.
IMAGE SOURCE: GETTY IMAGES.
On June 1, the biotech company announced results for a trial testing remdesivir in COVID-19 patients with evidence of pneumonia, but without reduced oxygen levels. They showed that COVID-19 patients given a 5-day course of the antiviral alongside standard of care had better outcomes than those receiving standard of care alone. Specifically, more remdesivir patients scored better on a 7-point scale incorporating clinical results, such as hospital discharge and ventilator support, than patients in the control arm of the study.
Source Fool.com
